1 - 25 of 144 results for author:"Van Damme J." in Literature citations
Results Customize
› Repeat search in UniProtKB (530)
| Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. Mortier A., Berghmans N., Ronsse I., Grauwen K., Stegen S., Van Damme J., Proost P. PLoS ONE 6:e23913-e23913(2011) · Mapped (1) |
| CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. El-Asrar A.M., Al-Obeidan S.S., Kangave D., Geboes K., Opdenakker G., Van Damme J., Struyf S. Immunobiology 216:1004-1009(2011) · Mapped (3) |
| CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. Gouwy M., Struyf S., Berghmans N., Vanormelingen C., Schols D., Van Damme J. Eur. J. Immunol. 41:963-973(2011) · Mapped (24) |
| Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Verbeke H., Struyf S., Berghmans N., Van Coillie E., Opdenakker G., Uyttenhove C., Van Snick J., Van Damme J. Cancer Lett. 302:54-62(2011) · Mapped (1) |
| The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Vandercappellen J., Van Damme J., Struyf S. Cytokine Growth Factor Rev. 22:1-18(2011) · Mapped (1) |
| Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Struyf S., Salogni L., Burdick M.D., Vandercappellen J., Gouwy M., Noppen S., Proost P., Opdenakker G., Parmentier M., Gerard C. et al. Blood 117:480-488(2011) · Mapped (2) |
| Cardiovascular determinants and prognostic significance of CC Chemokine Ligand-18 (CCL18/PARC) in patients with stable coronary artery disease. De Sutter J., Struyf S., Van de Veire N.R., Philippe J., De Buyzere M., Van Damme J. J. Mol. Cell. Cardiol. 49:894-896(2010) · Mapped (1) |
| Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity. Mortier A., Loos T., Gouwy M., Ronsse I., Van Damme J., Proost P. J. Biol. Chem. 285:29750-29759(2010) · Mapped (13) |
| Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes. Abu El-Asrar A.M., Struyf S., Opdenakker G., Van Damme J., Geboes K. Mol. Vis. 16:1098-1107(2010) · Mapped (9) |
| Interleukin-17 regulates chemokine and gelatinase B expression in fibroblasts to recruit both neutrophils and monocytes. Qiu Z., Dillen C., Hu J., Verbeke H., Struyf S., Van Damme J., Opdenakker G. Immunobiology 214:835-842(2009) · Mapped (3) |
| Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation. Loos T., Opdenakker G., Van Damme J., Proost P. Haematologica 94:1346-1353(2009) · UniProtKB (1) |
| The atypical kinase Cdk5 is activated by insulin, regulates the association between GLUT4 and E-Syt1, and modulates glucose transport in 3T3-L1 adipocytes. Lalioti V., Muruais G., Dinarina A., van Damme J., Vandekerckhove J., Sandoval I.V. Proc. Natl. Acad. Sci. U.S.A. 106:4249-4253(2009) · Mapped (3) |
| Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Struyf S., Proost P., Vandercappellen J., Dempe S., Noyens B., Nelissen S., Gouwy M., Locati M., Opdenakker G., Dinsart C. et al. Eur. J. Immunol. 39:843-857(2009) · Mapped (2) |
| Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. Proost P., Loos T., Mortier A., Schutyser E., Gouwy M., Noppen S., Dillen C., Ronsse I., Conings R., Struyf S. et al. J. Exp. Med. 205:2085-2097(2008) · UniProtKB (1) · Mapped (5) |
| Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Loos T., Mortier A., Gouwy M., Ronsse I., Put W., Lenaerts J.P., Van Damme J., Proost P. |
| Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Gouwy M., Struyf S., Noppen S., Schutyser E., Springael J.Y., Parmentier M., Proost P., Van Damme J. Mol. Pharmacol. 74:485-495(2008) · Mapped (6) |
| CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Van den Steen P.E., Deroost K., Van Aelst I., Geurts N., Martens E., Struyf S., Nie C.Q., Hansen D.S., Matthys P., Van Damme J. et al. Eur. J. Immunol. 38:1082-1095(2008) · Mapped (12) |
| Atypical Mowat-Wilson patient confirms the importance of the novel association between ZFHX1B/SIP1 and NuRD corepressor complex. Verstappen G., van Grunsven L.A., Michiels C., Van de Putte T., Souopgui J., Van Damme J., Bellefroid E., Vandekerckhove J., Huylebroeck D. Hum. Mol. Genet. 17:1175-1183(2008) · Mapped (34) |
| Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. Vandercappellen J., Noppen S., Verbeke H., Put W., Conings R., Gouwy M., Schutyser E., Proost P., Sciot R., Geboes K. et al. J. Leukoc. Biol. 82:1519-1530(2007) · Mapped (2) |
| Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Schutyser E., Su Y., Yu Y., Gouwy M., Zaja-Milatovic S., Van Damme J., Richmond A. Eur. Cytokine Netw. 18:59-70(2007) · Mapped (2) |
| Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Proost P., Mortier A., Loos T., Vandercappellen J., Gouwy M., Ronsse I., Schutyser E., Put W., Parmentier M., Struyf S. et al. Blood 110:37-44(2007) · Mapped (11) |
| Protective role of IFN-gamma in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. Kelchtermans H., Struyf S., De Klerck B., Mitera T., Alen M., Geboes L., Van Balen M., Dillen C., Put W., Gysemans C. et al. J. Leukoc. Biol. 81:1044-1053(2007) · Mapped (31) |
| Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. Fan X., Patera A.C., Pong-Kennedy A., Deno G., Gonsiorek W., Manfra D.J., Vassileva G., Zeng M., Jackson C., Sullivan L. et al. J. Biol. Chem. 282:11658-11666(2007) · Mapped (5) |
| Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Abu El-Asrar A.M., Struyf S., Kangave D., Geboes K., Van Damme J. Eur. Cytokine Netw. 17:155-165(2006) · Mapped (1) |
| A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Martens E., Leyssen A., Van Aelst I., Fiten P., Piccard H., Hu J., Descamps F.J., Van den Steen P.E., Proost P., Van Damme J. et al. Biochim. Biophys. Acta 1770:178-186(2007) · Mapped (7) |